en · de · es · fr · pt
cardarine-notes.peptides9000.com › Guide › Identity And Regulatory Status — Quick Reference

Identity And Regulatory Status — Quick Reference

By Editorial Desk · published 2025-11-04 · last reviewed 2025-12-11 · Guide

The short version of WADA Prohibited List fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-12-11 and is reviewed periodically as new material appears.

Identity and Regulatory Status

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.

Regulatory Status and Detection Context

Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.

A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.

Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.

Cardarine at a glance

PropertyValueNotes
Common synonymsGW501516; GW-1516; endurobolGW501516 is the research code
Drug classPPARδ agonistNot a selective androgen receptor modulator
Molecular formulaC21H18F3NO3S2Established chemical formula
Molar mass453.5 g/molCalculated from the formula
Regulatory statusProhibited in sport; not approved as medicineStatus varies by country

Detection, Regulation, and Quality Context

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Related pages on this site

Detection, Stability, and Quality

Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.

Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.

Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.

Supporting material

== Applications == With an expanded genetic code, the unnatural amino acid can be genetically directed to any chosen site in the protein of interest. The high efficiency and fidelity of this process allows a better control of the placement of the modification compared to modifying the protein post-translationally, which, in general, will target all amino acids of the same type, such as the thiol group of cysteine and the amino group of lysine. Also, an expanded genetic code allows modifications to be carried out in vivo. The ability to site-specifically direct lab-synthesized chemical moieties into proteins allows many types of studies that would otherwise be extremely difficult, such as:

=== 1975 leadership election === Heseltine had lost faith in Heath over the second miners' strike and over Heath's personal abrasiveness (Heath had apparently once told him to his face that he was too openly ambitious); his patron Peter Walker had also come to have similar doubts about Heath. Ten days before the October 1974 election, at which Heseltine bucked the national swing by increasing his majority at Henley, he urged Heath to consider his position by the end of the year. It is unclear how Heseltine voted in the first ballot of the 1975 Conservative leadership election, in which the challenger Margaret Thatcher defeated Heath. Norman Tebbit stated that he and John Nott persuaded him to vote for Thatcher so as to open up the way for his preferred candidate Willie Whitelaw to stand on the second ballot. Another (anonymous) close friend later told Michael Crick that Heseltine voted for Thatcher. The Thatcher team had him down as an abstainer, while he refused at the time to reveal how he voted. In his memoirs Heseltine wrote that he abstained in the first ballot, but that he would have voted for Whitelaw in the first ballot had he stood against Heath. Whitelaw admired his drive and energy but looked down on him as "new Money" and is said to have commented that Heseltine was "the sort of man who combs his hair in public". Heseltine toyed with standing himself for the second ballot (in Crick's view his vote would very likely have been derisory), but voted for Whitelaw.

American biochemist and geneticist at the NIH, who showed that UUU codes for phenylalanine, the first step in deciphering the genetic code. Nobel Prize in Physiology or Medicine (1968). Member Natl. Acad. Sci. USA. Roland Victor Norris (1888–1950). British biochemist at the Indian Institute of Science, who worked on glycogen metabolism and yeast fermentation, and later pioneered biochemistry in India. Paul Nurse FRS (President) (b. 1949). British geneticist at the Rockefeller University, who worked on control of the cell cycle. Nobel Prize in Physiology or Medicine (2001)

The Furman is a unit of angular measure equal to 1⁄65,536 of a circle, or just under 20 arcseconds. It is named for Alan T. Furman, the American mathematician who adapted the CORDIC algorithm for 16-bit fixed-point arithmetic sometime around 1980. 16 bits give a resolution of 216 = 65,536 distinct angles. A related unit of angular measure equal to 1⁄256 of a circle, represented by 8 bits, has found some use in machinery control where fine precision is not required, most notably crankshaft and camshaft position in internal combustion engine controllers, and in video game programming. There is no consensus as to its name, but it has been called the 8-Bit Furman. These units are convenient because binary integer overflow resembles angular arithmetic: the value of an 8-bit integer overflows from 255 to 0 when a full circle has been traversed. This means binary addition and subtraction work as expected for angular arithmetic. Measures are often made using a Gray code, which is trivially converted into more conventional notation. Its value is equivalent to about 0.0245 radians or 1.41°.

Sources: en.wikipedia.org

Notes from published material

== Nomenclature == Usually, a "phenyl group" is synonymous with C6H5− and is represented by the symbol Ph (archaically, Φ), or Ø. Benzene is sometimes denoted as PhH. Phenyl groups are generally attached to other atoms or groups. For example, triphenylmethane (Ph3CH) has three phenyl groups attached to the same carbon center. Many or even most phenyl compounds are not described with the term "phenyl". For example, the chloro derivative C6H5Cl is normally called chlorobenzene, although it could be called phenyl chloride. In special (and rare) cases, isolated phenyl groups are detected: the phenyl anion (C6H−5), the phenyl cation (C6H+5), and the phenyl radical (C6H•5). Although Ph and phenyl uniquely denote C6H5−, substituted derivatives also are described using the phenyl terminology. For example, C6H4NO2− is nitrophenyl, and C6F5− is pentafluorophenyl. Monosubstituted phenyl groups (that is, disubstituted benzenes) are associated with electrophilic aromatic substitution reactions and the products follow the arene substitution pattern. So, a given substituted phenyl compound has three isomers, ortho (1,2-disubstitution), meta (1,3-disubstitution) and para (1,4-disubstitution). A disubstituted phenyl compound (trisubstituted benzene) may be, for example, 1,3,5-trisubstituted or 1,2,3-trisubstituted. Higher degrees of substitution, of which the pentafluorophenyl group is an example, exist and are named according to IUPAC nomenclature.

On 4 January 2023, it was reported that Brazil was seeking an Amazon summit between members of the Amazon Cooperation Treaty Organization (ACTO) and other non-members, which was reportedly well received by the ACTO countries. On 26 January, Lula invited French president Emmanuel Macron to attend the ACTO summit due to the French department of French Guiana location in the Amazon region.

== Peptide nucleic acids == Peptide nucleic acid (PNA) is a nucleic acid in which natural nucleic acid has been replaced by a synthetic peptide backbone formed from N-(2-amino-ethyl)-glycine units along with sugar phosphate backbone forming in an achiral and uncharged moiety that mimics RNA or DNA oligonucleotides. PNA cannot be degraded inside living cells but it is chemically stable and resistant to hydrolytic (enzymatic) cleavage.

Sources: en.wikipedia.org

Further detail

Norman Geras (25 August 1943 – 18 October 2013); political theorist of Rhodesian Jewish origin; Professor Emeritus of Politics at the University of Manchester; author of over ten scholarly and historical texts, mostly focused on radical politics; contributed to analysis of Karl Marx in Marx and Human Nature; in 2006, he was one of the principal authors of the Euston Manifesto. Martin Gilbert (25 October 1936 – 3 February 2015); historian and honorary Fellow of Merton College, Oxford; author of 88 books, including works on Winston Churchill, the 20th century, and Jewish history including the Holocaust; was a member of the Chilcot Inquiry into Britain's role in the Iraq War; noted for his endorsement of Bat Ye'or and Eurabia theory, providing comment for her book, stating that the theory "is 100 percent accurate". One of Gilbert's last books, In Ishmael's House: A History of the Jews in Muslim Lands cited Ye'or with approval several times. Morris Ginsberg FBA (14 May 1889 – 31 August 1970) British sociologist and prolific author who played a key role in the development of the discipline of sociology. He served as editor of The Sociological Review in the 1930s and later became the founding chairman of the British Sociological Association in 1951 and its first President (1955–1957). He was president of the Aristotelian Society from 1942 to 1943, and helped draft the UNESCO 1950 statement titled The Race Question.

The monocyte monolayer assay (MMA) is used to determine the clinical significance of alloantibodies produced by blood transfusion recipients. The assay is used to assess the potential for intravascular hemolysis when incompatible cellular blood products are transfused to the anemic patient. When donor cells possess substances that are not produced by the recipient, the recipient's immune system produces antibodies against the substance; these are called alloantibodies. Specific white blood cells, called monocytes, are tasked with ingesting foreign material and become activated during certain inflammatory events. These activated monocytes come in contact with antibody-sensitized red blood cells (RBC) and may or may not exhibit phagocytosis (ingestion) and destroy the donor red blood cells. If monocytes destroy the RBC, the antibody attached to those RBC is considered clinically significant.

== History == The British have had a system of heroin maintenance since the 1920s. For decades it supplied a few hundred addicts nationwide, most of whom were doctors themselves. It was de-emphasized considerably during the 1960s-1980s as a result of the U.S.-led war on drugs. In the 1980s and early 1990s, Dr John Marks ran heroin-prescribing clinics in Liverpool, Widnes and Warrington that were highly controversial. Because of the lack of large-scale trials, only anecdotal evidence existed as to the efficacy of the treatment. This changed in 1994 when Switzerland, faced with one of the largest open drug scenes in Europe at the time, started large-scale trials on the potential use of diamorphine as a maintenance drug. They proved diamorphine to be a viable maintenance drug which has shown equal or better rates of success than methadone in terms of assisting long-term users establish stable, crime-free lives. These results encouraged countries like Germany and the Netherlands to conduct their own trials and finally to include heroin-assisted treatment fully as a part of the national health system in 2009. In Switzerland, heroin has been made available under supervision to addicts since around 1994. Several studies have been conducted between 1994 and 1996.

=== Pharmacodynamics === Similarly to MDMA, SDMA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA) and a non-selective serotonin 5-HT2 receptor agonist. However, SDMA was 11-fold more potent as a serotonin releaser, 19-fold more potent as a dopamine releaser, and 2-fold more potent as a norepinephrine releaser than MDMA in HEK293 cells in vitro. In addition, it was about twice as potent as a serotonin 5-HT2A receptor agonist, whereas it showed similar agonistic potency as MDMA at the serotonin 5-HT2B and 5-HT2C receptors. SDMA had similar activational efficacies at the serotonin 5-HT2 receptors as MDMA. Due to its greater potency as a monoamine releasing agent, SDMA may be active at lower doses or concentrations than MDMA. SDMA produced hyperlocomotion and hyperthermia in rodents with similar profiles as MDMA. However, SDMA did not produce rewarding effects in the conditioned place preference (CPP) paradigm unlike MDMA. Hence, SDMA might have reduced misuse potential compared to MDMA. As with MDMA, SDMA did not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence may not produce hallucinogenic effects in humans. SDMA might be less cardiotoxic than MDMA due to having much greater monoamine-releasing potency but unaltered serotonin 5-HT2B receptor agonistic potency.

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine a SARM?

No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.

Is cardarine approved for human use?

No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.

Why was its development discontinued?

Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.

Is cardarine approved for any medical use?

No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.

Network